A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials.
INTRODUCTION:Enrolling cancer patients in phase I clinical trials (P1s) requires that they fulfill specific criteria. Between the time they sign the consent form and the 1st administration of the experimental drug, some patients may be excluded and considered as screen failures (SFs). Our objective...
Main Authors: | Emmanuelle Kempf, Nathalie Lemoine, Gabrielle Tergemina-Clain, Anthony Turpin, Sophie Postel-Vinay, Emilie Lanoy, Jean-Charles Soria, Christophe Massard, Antoine Hollebecque |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4858154?pdf=render |
Similar Items
-
MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies
by: Patricia Martin Romano, et al.
Published: (2019-06-01) -
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA
by: Clémence Astier, et al.
Published: (2024-01-01) -
Beyond DNA repair: the novel immunological potential of PARP inhibitors
by: Roman M. Chabanon, et al.
Published: (2019-03-01) -
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
by: Carine Ngo, et al.
Published: (2022-03-01) -
Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
by: Patricia Martin-Romano, et al.
Published: (2021-11-01)